New hope for Tough-to-Treat colon cancer: experimental drug combo enters human testing
NCT ID NCT06936527
Summary
This study is testing whether adding an experimental drug called XS-03 to standard chemotherapy combinations helps control metastatic colorectal cancer that has a specific genetic change called a RAS mutation. The trial will first find the safest dose of XS-03, then see if the new combinations shrink tumors better than standard treatment alone. It aims to enroll about 102 adults with this advanced form of cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.